Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Clin Cancer Res. 2016 May 16;22(21):5362–5369. doi: 10.1158/1078-0432.CCR-15-2889

Table 3.

Differential risk stratification of patients with discordant scores based on Clinical Oncotype Dx and NanoString Oncotype Dx recurrence scores

Number of Patients Risk from Clinical Oncotype Dx recurrence scores (clinRS) Risk from NanoString Oncotype Dx recurrence scores (nstringRS)
7/71 (9.9%) Low Intermediate
4/71 (5.6%) Intermediate High
5/71 (7.0%) Intermediate Low
1/71 (1.4%) High Intermediate